Peripheral blood microRNA biomarker for early diagnosis of pancreatic cancer and application thereof
Through the proposed four blood microRNA biomarkers miR-139-3p, miR-92b-5p, miR-1976 and miR-1908-5p, the problem of early diagnosis of pancreatic cancer is solved, and the diagnosis of pancreatic cancer patients is achieved. The six-year risk warning has been provided, which has improved the accuracy of diagnosis and survival rate.
Patent Information
- Application Number
- CN202411174492.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-26
AI Technical Summary
There is a lack of effective microRNA biomarkers for early diagnosis of pancreatic cancer in the prior art, resulting in the fact that pancreatic cancer patients often have local lesions or distal metastasis when diagnosed, which makes early diagnosis difficult and affects survival.
Four new blood microRNA biomarkers miR-139-3p, miR-92b-5p, miR-1976 and miR-1908-5p are proposed to provide risk warnings six years before pancreatic cancer patients diagnosed through non-invasive detection methods. , and combined with a kit for the diagnosis of pancreatic cancer.
These markers were verified in the prospective cohort to have high sensitivity and specificity, and can provide risk warnings in the first three years of pancreatic cancer diagnosis, improving the accuracy and prediction window for early diagnosis of pancreatic cancer, with AUC reaching 0.847, sensitivity and The specificity was 82.8% and 72.0%, respectively.
Smart Images

Figure CN118932065A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of medical molecular biology, and more specifically, relates to peripheral blood microRNA biomarkers for early diagnosis of pancreatic cancer and applications thereof, and in particular to four peripheral blood microRNA biomarkers for early diagnosis of pancreatic cancer. Background Art
[0002] Pancreatic cancer is the third leading cause of death among common malignant tumors. As one of the most deadly malignant tumors, the 5-year relative survival rate of pancreatic cancer patients is only about 10%. Since there are no specific symptoms in the early stage of pancreatic cancer, about 80% of patients have local lesions or distant metastases when diagnosed. Compared with advanced patients, the survival of patients diagnosed early can be increased by about 30%. In addition, the evolution of pancreatic cancer is slow. It takes an average of 11.7 years from the occurrence of pancreatic cancer to tumor invasion, which provides a longer window period for early detection of pancreatic cancer (S. Yachida, S. Jones, I. Bozic, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 2010, 467 (7319): 1114-1117). Therefore, early screening and intervention are of great significance for improving the survival rate of pancreatic cancer patients.
[0003] MicroRNAs are a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides. They can interact with their specific target genes and are important post-transcriptional regulatory factors. In normal physiological processes in the human body, microRNAs can be released by cells into the peripheral blood and act as signaling molecules to regulate intercellular communication. Therefore, abnormal secretion of microRNAs may indicate the occurrence and development of diseases in the body, including tumorigenesis. In addition, microRNAs exist stably in the blood in a form that resists RNase activity, which further highlights their great potential as disease biomarkers.
[0004] In the past few decades, a large number of studies have reported circulating microRNAs markers associated with pancreatic cancer. However, most studies are limited to a few to dozens of microRNAs, representing only a small part of the approximately 2,600 mature microRNAs recorded in miRBase. Only a few studies are based on systematic microRNA expression profiles, such as using microRNA assays, microarray chips (microarray) or sequencing methods to quantify microRNA expression. Compared with CA19-9, existing microRNAs markers can significantly improve the predictive accuracy of pancreatic cancer. However, these findings have not yet been validated in prospective studies. To date, only miR-10b, miR-21-5p, miR-30c and miR-106b have been validated in a nested case-control study based on a European cohort, and their role in predicting pancreatic cancer risk is only reflected within 2 years before diagnosis (EJ Duell, L. Lujan-Barroso, N. Sala, et al. Plasma micrornas as biomarkers of pancreatic cancer risk in a prospective cohort study. International Journal of Cancer, 2017, 141(5): 905-915). Summary of the invention
[0005] In view of the above problems, the technical problem to be solved by the present invention is to overcome the lack of microRNA biomarkers that can be used for the early diagnosis of pancreatic cancer in the prior art, and provide four new blood microRNA biomarkers that can be used for the early diagnosis of pancreatic cancer based on a prospective cohort. The markers are used for the early diagnosis of pancreatic cancer in a non-invasive manner, and risk warning can be provided up to six years before the diagnosis of pancreatic cancer patients.
[0006] According to a first aspect of the present invention, there is provided a microRNA biomarker for diagnosis of pancreatic cancer, characterized in that the microRNA biomarker is at least one of miR-139-3p, miR-92b-5p, miR-1976 and miR-1908-5p;
[0007] The nucleotide sequence of the miR-139-3p is shown in SEQ ID NO:1, the nucleotide sequence of the miR-92b-5p is shown in SEQ ID NO:2, the nucleotide sequence of the miR-1976 is shown in SEQ ID NO:3, and the nucleotide sequence of the miR-1908-5p is shown in SEQ ID NO:4.
[0008] According to another aspect of the present invention, a kit for diagnosing pancreatic cancer is provided, wherein the kit comprises the microRNA biomarker.
[0009] According to another aspect of the present invention, there is provided the use of the microRNA biomarker in the preparation of a pancreatic cancer diagnostic reagent.
[0010] In general, the above technical solution conceived by the present invention has the following technical advantages compared with the prior art:
[0011] (1) The present invention is based on human blood samples, and the detection method is safe and non-invasive, with high acceptance among asymptomatic people, which is conducive to the early diagnosis of pancreatic cancer.
[0012] (2) Based on prospective cohort samples with an average follow-up time of about 5.7 years, the present invention identified and verified four blood microRNA biomarkers for early diagnosis of pancreatic cancer. These markers can provide early warning of pancreatic cancer risk three years before the diagnosis of pancreatic cancer, and have the advantage of a long prediction window.
[0013] (3) The microRNA biomarker of the present invention has high accuracy and high sensitivity and specificity for pancreatic cancer. The AUC of the combination of the four microRNAs of the present invention can reach 0.847, with a sensitivity and specificity of 82.8% and 72.0%, respectively. The microRNA biomarker of the present invention can be combined with other clinical diagnostic methods to provide a more accurate method for early diagnosis of pancreatic cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 are the expression levels of the four biomarkers at different pre-diagnosis stages.
[0015] Figure 2 are the expression levels of the four biomarkers in different tumor stages.
[0016] Figure 3 Figure 2 is the ROC analysis of four biomarkers and their combination for differentiating pancreatic cancer from healthy controls. DETAILED DESCRIPTION
[0017] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0018] The purpose of the present invention is to identify and validate blood microRNA biomarkers associated with new pancreatic cancer in a prospective cohort. The blood microRNA biomarkers include miR-139-3p (MIMAT0004552), miR-92b-5p (MIMAT0004792), miR-1976 (MIMAT0009451) and miR-1908-5p (MIMAT0007881).
[0019] The nucleotide sequence of the miR-139-3p is shown in SEQ ID NO: 1 (UGGAGACGCGGCCCUGUUGGAGU), the nucleotide sequence of the miR-92b-5p is shown in SEQ ID NO: 2 (AGGGACGGGACGCGGUGCAGUG), the nucleotide sequence of the miR-1976 is shown in SEQ ID NO: 3 (CCUCCUGCCCUCCUUGCUGU), and the nucleotide sequence of the miR-1908-5p is shown in SEQ ID NO: 4 (CGGCGGGGACGGCGAUUGGUC).
[0020] The blood expression levels of miR-139-3p, miR-92b-5p, miR-1976 and miR-1908-5p of the present invention are positively correlated with the risk of developing new pancreatic cancer in the general population.
[0021] According to a specific embodiment of the present invention, the reagent materials and / or instrument equipment for detecting the level of microRNA in a sample from an individual to be tested include the reagent materials and / or instrument equipment used in the following methods:
[0022] microRNA second-generation sequencing detection method and microRNA chip detection method.
[0023] Furthermore, the present invention evaluates the application of the blood microRNA biomarker in the early diagnosis of pancreatic cancer.
[0024] Preferably, the differential blood expression of miR-139-3p, miR-92b-5p, miR-1976 and miR-1908-5p in new pancreatic cancer patients can be found three to six years before the diagnosis of pancreatic cancer.
[0025] Preferably, the blood differential expression of miR-139-3p, miR-92b-5p, miR-1976 and miR-1908-5p can be found in pancreatic cancer patients with tumor classification stage III and below.
[0026] Preferably, the combination marker of the four microRNAs can effectively predict pancreatic cancer patients in the validation data set, and the model AUC is 0.847.
[0027] The following are specific embodiments
[0028] Example 1: Collection of research subjects and data generation
[0029] This study is based on the data collected in 2013 from the Dongfeng-Tongji (DFTJ) cohort as a baseline, with an average follow-up time of 5.7 years. Each case was matched with a control according to the same gender, the same enrollment hospital, age ±1.2 years and blood collection date difference ±7 days. A nested case-control study of 44 pairs of newly diagnosed pancreatic cancer was designed and established.
[0030] The plasma samples used in the present invention were fasting blood samples collected from the DFTJ cohort in 2013. The plasma, serum and blood clots were separated and packaged by immediate centrifugation. The biological samples were stored in a -80°C refrigerator and entered into the electronic database of biological samples. The present invention first selected about 500 μL of plasma samples and used Plasma total RNA was extracted by LS lysate pretreatment combined with miRNeasySerum / Plasma Kit (catalog no.217184). Then, 5ul of plasma total RNA was used as the starting RNA template, and the QIAseq microRNA Library Kit (catalog no.331502, QIAGEN) was selected to construct a micro-library of plasma microRNA. The experimental process was strictly in accordance with the QIAseq microRNA Library Kit Handbook, and finally the sequencing of small RNA was completed on the IlluminaNextSeq500 platform (single-end sequencing, 75bp).
[0031] For the original sequencing data, the present invention uses FastQC software (version 0.11.8) to perform quality control on the original sequencing data, confirm that there are no abnormal samples, and the non-repetitive sequence readings of all samples are greater than 9M, and perform subsequent sequence alignment and quantitative analysis. Remove low-quality readings (quality score less than 20), use miRge3.0 software to remove the adapter sequence, and use the unique molecular identifier (UMI) to mark the sequence, avoiding the repeated DNA fragments generated during PCR amplification, resulting in repeated counts or deviations in subsequent data. The sequence alignment of mature microRNA is based on the miRBase database (version 22, http: / / www.mirbase.org / ), and the default settings in miRge3.0 are used to quantify microRNA, and the expression levels of 1214 expressed microRNAs are obtained. Since the alignment rate (aligned reading / total reading) of 5 samples is less than 40%, the present invention removes these low alignment rate samples and their corresponding matching samples, including a total of 4 sample pairs. Finally, 40 pairs of new pancreatic cancer case-control samples were retained for downstream analysis.
[0032] The present invention describes and compares the baseline differences in basic characteristics, lifestyle and blood sugar-related traits between the new pancreatic cancer case group and the healthy control group, including age, gender, body mass index (BMI), waist-to-height ratio, smoking status, drinking status, fasting blood sugar and HbA1c. As shown in Table 1, the mean (standard deviation) age of the new pancreatic cancer cases was 69.38 (8.02) years old, and 42% were male; the differences in baseline information mainly existed in blood sugar-related indicators, including fasting blood sugar, glycosylated hemoglobin and type 2 diabetes, which were significantly increased in the new pancreatic cancer group.
[0033] Table 1 Baseline information and comparison of new pancreatic cancer cases and matched controls
[0034]
[0035]
[0036] Note: Type 2 diabetes is defined as a self-reported history of type 2 diabetes, a history of using hypoglycemic drugs or insulin, fasting blood glucose ≥ 7.0 mmol / L or HbAlc ≥ 6.5%. Continuous variables are expressed as mean ± standard deviation, and categorical variables are expressed as number (percentage). P is the difference test result between the new case group and the matched control group, where continuous variables are tested using paired t-tests and categorical variables are tested using Cochran-Mantel-Haenszel tests.
[0037] Example 2: Screening and verification of pancreatic cancer-related peripheral blood microRNA markers
[0038] (1) Identification of peripheral blood microRNA markers associated with new pancreatic cancer
[0039] First, the ComBat model based on negative binomial regression was used to correct for batch effects. Then, 746 microRNAs expressed in less than 25% of the samples (counts per million, CPM>1) were removed, and a total of 771 microRNAs were included for subsequent analysis. The DESeq2 method was used to identify differentially expressed microRNAs in new pancreatic cancer and control samples, and the model was adjusted for age, sex, admission hospital, and type 2 diabetes. The differences between the groups were quantified using the log2-transformed fold change (log2FC) indicator. The Benjamini-Hochberg method was used to calculate the FDR to correct the P value, and the significance level was defined as FDR<0.05.
[0040] As shown in Table 2 , a total of 21 microRNAs were associated with new pancreatic cancer, including miR-6852-5p, miR-6764-5p, miR-769-3p, miR-139-3p, miR-1270, miR-92b-5p, miR-486-5p, miR-1180-3p, miR-106b-3p, miR-1976, mi R-12136, miR-1908-5p, miR-501-3p, miR-5187-5p, miR-3138, and miR-1306-3p were positively correlated with the risk of incident pancreatic cancer, whereas miR-141-3p, miR-30e-5p, miR-338-3p, miR-199b-5p, and miR-128-3p were negatively correlated with the risk of incident pancreatic cancer.
[0041] Table 2 Preliminary screening of 21 microRNA biomarkers associated with new pancreatic cancer
[0042]
[0043] (2) Validation of peripheral blood microRNA markers associated with new pancreatic cancer
[0044] The 21 biomarkers screened in (1) were validated based on data from a Japanese clinical study. The data included 100 pancreatic cancer patients admitted to the National Cancer Center East Hospital in Japan between 2010 and 2012. All patients were histologically confirmed to have adenocarcinoma by pathological diagnosis. In addition, 150 healthy individuals recruited from Toray Industries Inc.'s Japanese subsidiary in 2013 were included as controls. The inclusion criteria for healthy control individuals were age greater than 60 years, no history of cancer, and no hospitalization in the past 3 months. Using the Human microRNA Oligo Chip (Toray Industries, Inc.), 2555 mature microRNAs were measured in the serum samples of each participant. The present invention removed one pancreatic cancer patient with missing demographic information, and a total of 99 pancreatic cancer patients and 150 healthy controls were included for subsequent validation analysis.
[0045] Among the 21 candidate biomarkers, a total of 9 microRNAs, miR-30e-5p, miR-769-3p, miR-139-3p, miR-92b-5p, miR-486-5p, miR-106b-3p, miR-1976, miR-1908-5p, and miR-3138, were expressed in more than 25% of the samples (signal values greater than 2 6 ). To avoid the influence of extreme values, this study performed 90% winsorization processing on each microRNA based on the standardized microRNA matrix, replacing expression values greater than the 95% quantile with the 95% quantile value, and replacing signal values less than the 5% quantile with the 5% quantile value. Then, each microRNA was standardized using Z transformation. A logistic regression model was used to adjust for gender and age at diagnosis, and the odds ratio (OR) value and its 95% confidence interval (CI) were reported to reflect the effect size of microRNA on pancreatic cancer. The significance level was a Bonferroni-corrected P value of less than 0.05.
[0046] As can be seen from Table 3, miR-139-3p, miR-92b-5p, miR-1976 and miR-1908-5p have the same effect direction with the risk of pancreatic cancer in the discovery data and verification data, and are all significantly correlated.
[0047] Table 3 Verification of the association between 4 miRNA markers and the risk of pancreatic cancer
[0048]
[0049] Example 3: Detectability of four biomarkers at different progression stages
[0050] Based on the discovery cohort, the present invention explored the changes in microRNA markers with the time interval of pancreatic cancer diagnosis, where the time interval was represented by the follow-up time from baseline to pancreatic cancer diagnosis. Specifically, according to the follow-up time from baseline to pancreatic cancer diagnosis, new pancreatic cancer patients were divided into a group every 3 years, resulting in a total of two groups, of which 26 were diagnosed with pancreatic cancer within 3 years after baseline, and the remaining 14 were diagnosed after 3 years. For each microRNA marker, linear regression was used to correct for gender, baseline age, and admission hospital, and the residual value was taken, and the Wilcoxon test was used to compare the differences between each new pancreatic cancer subgroup and the control group. By Figure 1 As shown, based on the discovery cohort data, miR-139-3p (P=0.034) and miR-92b-5p (P=0.031) could indicate the occurrence of pancreatic cancer more than 3 years from baseline, and miR-1908-5p (P=0.038) and miR-1976 (P=0.013) had significant differences in the case subgroup within 3 years.
[0051] Based on the validation data set, the present invention explored the expression of microRNA markers in different pancreatic cancer tumor stages. Among the 99 pancreatic cancer patients, there were 16 stage II pancreatic cancer patients, 27 stage III patients, 54 stage IV patients and 2 patients with only neoadjuvant pathologic stages (ypStage). After removing the two ypStage patients, linear regression was used to correct for gender and diagnosis age to obtain the residual value of each microRNA, and the Wilcoxon test was used to compare the differences between the case subgroups and the control group at different stages. Figure 2 As shown, compared with the control samples, miR-1908-5p (P = 0.003), miR-139-3p (P = 0.009) and miR-1976 (P = 9 × 10 -4 ) is significantly increased in stage II tumor.
[0052] Example 4: Predictive effects of four biological markers and their combination on pancreatic cancer
[0053] This chapter is based on the JNCCHE study. The leave-one-out crossvalidation (LOOCV) method was used to evaluate the predictive performance of miRNA markers by drawing ROC graphs and calculating the area under the ROC curve (AUC). In addition, the predictive performance of miRNA markers was evaluated by fixing the specificity to 0.80 and calculating the corresponding accuracy, sensitivity, positive predictive value, and negative predictive value.
[0054] Figure 3 Table 4 shows the prediction effect of four miRNA markers in the validation data set. The results show that the AUC of the four microRNAs is above 0.7, among which the AUC of the combination marker is the highest, which is 0.847 (0.798, 0.896). Taking the maximum value of Youden index as the critical value, the sensitivity and specificity of the combination marker are 82.8% and 72.0%, respectively. In addition, when the fixed specificity is 0.80, the prediction accuracy, sensitivity, positive predictive value and negative predictive value of the combination marker reach 0.771 (0.769, 0.772), 0.727 (0.639, 0.815), 0.705 (0.617, 0.794) and 0.816 (0.753, 0.878), respectively.
[0055] Table 4 Predictive effects of four miRNA markers in the JNCCHE study
[0056]
[0057]
[0058] Note: The estimation results in the above table are based on a fixed specificity of 0.80.
[0059] It will be easily understood by those skilled in the art that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. MicroRNA biomarkers for pancreatic cancer diagnosis, It is characterized in that The microRNA biomarker is at least one of miR-139-3p, miR-92b-5p, miR-1976 and miR-1908-5p; The nucleotide sequence of the miR-139-3p is shown in SEQ ID NO:1, the nucleotide sequence of the miR-92b-5p is shown in SEQ ID NO:2, the nucleotide sequence of the miR-1976 is shown in SEQ ID NO:3, and the nucleotide sequence of the miR-1908-5p is shown in SEQ ID NO:
4.
2. A kit for the diagnosis of pancreatic cancer, It is characterized in that The kit comprises the microRNA biomarker according to claim 1.
3. Use of the microRNA biomarker as claimed in claim 1 in the preparation of a pancreatic cancer diagnostic reagent.
Citation Information
Patent Citations
Method for detecting serum marker of pancreatic cancer
CN101613748A
Detection reagent of biomarker for early diagnosis of pancreatic cancer
CN111748629A
Biomarker for early diagnosis of pancreatic cancer and application
CN114540493A
Pancreatic cancer related serum microRNA marker and pancreatic cancer diagnosis method
CN118516459A
Biomarkers for renal cell carcinoma
US20230066287A1
